Chlamydia trachomatis: Aspectos microbiológicos, clínicos y epidemiológicos.

Chlamydia trachomatis: Aspectos microbiológicos, clínicos y epidemiológicos.

Published 2001-07-01

Open | Download
PDF (Spanish) FLIP
How to Cite
Matta, S., Arango, Álvaro I., & Visbal, J. (2001). Chlamydia trachomatis: Aspectos microbiológicos, clínicos y epidemiológicos. Journal MVZ Cordoba, 6(2). https://doi.org/10.21897/rmvz.528
doi

https://doi.org/10.21897/rmvz.528
Dimensions
PlumX
Salim Matta
Álvaro I. Arango
Jorge Visbal
Show authors biography

Salim Matta

Universidad de Córdoba, Facultad de Medicina Veterinaria y Zootecnia, Instituto de Investigaciones Biológicas del Trópico

Álvaro I. Arango

Universidad de Córdoba, Facultad de Medicina Veterinaria y Zootecnia, Instituto de Investigaciones Biológicas del Trópico

Jorge Visbal

Universidad de Córdoba, Facultad de Medicina Veterinaria y Zootecnia, Instituto de Investigaciones Biológicas del Trópico
Se presenta una revisión completa de los principales aspectos microbiológicos, clínicos y epidemiológicos de Chlamydia trachomatis. Se hace énfasis en los mecanismos particulares de invasividad, tipo de receptores, aspectos epidemiológicos y factores genéticos de susceptibilidad entre otros. Se abordan las patologías que ocasiona Chlamydia trachomatis separando las infecciones en el hombre, mujer y niños. También se realiza una actualización sobre los diferentes métodos de diagnóstico desde el cultivo celular hasta la biología molecular; se hace una reseña de C. psittaci y C. pneumoniae. Por último se tocan aspectos terapéuticos del tratamiento con énfasis en las infecciones por Chlamydia trachomatis

Article visits 3114 | PDF visits

Downloads

Download data is not yet available.
  1. Arango A I. Chlamydia y Rickettsia. En Máttar S, & Melo A, Editores. Bacteriología clínica: estudio etiológico de las enfermedades infecciosas de origen bacteriano. 1998; Editorial CEJA. Bogotá.
  3. Baehr W, Zhang, Y, Joseph T, Su H, Nano FE, Everett DE, et al: Mapping antigenic domains expressed by Chlamydia trachomatis major outer membrane protein genes. Proc Natl Acad Sci USA 1988; 85:4000-4004. http://dx.doi.org/10.1073/pnas.85.11.4000
  5. Bavoil P: Invation and Intracellular Growth of Chlamydia Species. En: Iglewski BH, Clark VI (Eds): Molecular Basis of Bacterial Pathogenesis. Academic Press. 1990.
  7. Bergeys Manual of Determinative Bacteriology, Ninth Edition, Willians & Wilkins Baltimore, USA 1994; 351.
  9. Black C. Current methods of laboratory diagnosis of Chlamydia trachomatis infections. Clin Microbiol Rev 1997; 10:160-184.
  11. Brunham RC, Peeling RW. Chlamydia trachomatis antigens: role in immunity and pathogenesis. Infect Agents Dis 1994; 3:218-33.
  13. Centers for Disease Control, Division of Sexually Transmitted Diseses: STD treatment guidelines. MMWR 1995; 34(4S).
  15. Dahlen G, J. Boman, L. S. Birgander, and P. Lindblom. LP (A) lipropotein, IgG, IgA, IgM antibodies to Chlamydia pneumoniae and HLA class II genotype in early coronary artery disease. Atherosclerosis 1995; 114 :165-174. http://dx.doi.org/10.1016/0021-9150(94)05480-7
  17. Fong I, Chiu B, Viira E, et al. Rabbit model for Chlamydia pneumoniae infection. J Clin Microbiol 1997; 35:48-52.
  19. Kapusnik-Uner JE, Sande MA, Chambers HF. Tetracyclines, Choramphenicol, Erytromycin, and Miscellaneous Antibacterial Agents in Goodman & Gilman's The pharmacological Basis of Therapeutics. Ninth Edition. The Mc Graw-Hill Companies. 1996; 1123-1153.
  21. Kuo CC, Shor A, Campbell L, Fukushi H, Patton D, Grayston JT. Demonstration of Chlamydia pneumoniae in Atherosclerotic Lesions of Coronary Arteries. J Infect Dis 1993; 167:841-9. http://dx.doi.org/10.1093/infdis/167.4.841
  23. Magid D, Douglas JM, Schwartz JS. Doxycycline compared with azithromycin for treating women with genital Chlamydia trachomatis infections: an incremental cost-effectiveness analysis. Ann Intern Med 1996; 124:389-99. http://dx.doi.org/10.7326/0003-4819-124-4-199602150-00002
  25. McClarty G. Chlamydiae and the biochemistry of intracellular parasitism. Trends Microbiol 1994; 2:157-64. http://dx.doi.org/10.1016/0966-842X(94)90665-3
  27. Melnick S. L, E. Shahar A. R. Fulsom J. T. Grayston P. D. Sorlie F. P. Wang. and M. Szkzo. Past infection by Chlamydia pneumoniae strain: TWAR and asymptomatic carotid atherosclerosis: atherosclerosis risk in communities (ARIC): study investigators. Am J Med 1993; 95:499-504. http://dx.doi.org/10.1016/0002-9343(93)90332-J
  29. Mendall M. A, D. Carrington D. Strachan, P. Patel, N. Molineaux J. Levi, T. Toosey A. K. Camm, and T. C. Northfield. Chlamydia pneumoniae: risk factor for seropositivy and association with coronary artery disease. J Infect 1995; 30:121-128. http://dx.doi.org/10.1016/S0163-4453(95)80006-9
  31. Mlot Ch. Probing Chamydia connection to atheroesclerosis. Asm- News 1996; 62:521.
  33. Morré SA, Sillekens P, Jacobs MV, Van Aarle P, Blok S, Van Gemen B, Jan M, Walboomers M, Chris J, Meijer LM, And Adriaan J, Van den Brule C. RNA Amplification by Nucleic Acid SequenceBased Amplification with an Internal Standard Enables Reliable Detection of Chlamydia trachomatis in Cervical Scrapings and Urine Samples. J Clin Microbiol. 1996; 34:3108-3114.
  35. Morrison RP, Belland RJ, Lyng D, Caldwell HD: Chlamydial disease pathogenesis. The 57 kDa chlamydial hypersensitivity antigen is a stress response protein. J Exp Med 1989; 25:170:1271
  37. Ossewaarde JM, Plantema FHF, Rieffe M, Nawrocki RP, de Vries A, Van Loon AM. Efficacy of single-dose azithromycin versus doxycycline in the treatment of cervical infections caused by Chlamydia trachomatis. Eur J Clin Microbiol Infect Dis 1992; 11:693-7. http://dx.doi.org/10.1007/BF01989972
  39. Patel P, M. A. Mendall D. Carrington D. P. Strauchan E. Leatham, N. Molienaux, J. Levi, C. Blakeston, C. A. Seymour, A. K. Camm et al. Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factor. Br Med J 1995; 311:711-714. http://dx.doi.org/10.1136/bmj.311.7007.711
  41. Peeling RW. Chlamydia trachomatis and Neisseria gonorrhoeae: Pathogens in retreat? Current Opinion in Infections Diseases 1995; 8:26-34. http://dx.doi.org/10.1097/00001432-199502000-00006
  43. Reese R, Bets R.Sulfonamides and TrimethropimSulfamethoxazole in Handbook of Antibiotics. Second Edition. Little, Brown and Company. Boston & New York. USA. 1993; 271-427.
  45. Schachter J, Grossman M, Azimi PH: Serology of Chlamydia trachomatis in infants. J Infect Dis 1982; 146: 53. http://dx.doi.org/10.1093/infdis/146.4.530
  47. Verkooyen RP, Luijendijk A, Huisman WM, Goessens WHF, Kluytmans JAJW, Van RijsoortVos JH, Verbrugh HA. Detection of PCR Inhibitors in Cervical Specimens by Using the Amplicor Chlamydia trachomatis Assay. J Clin Microbiol. 1996; 34:3072-3074.
  49. Woods ML, Robinson EN Jr., McGee ZA, Hitchcok PJ. Chlamydiae-Genital and Respiratory Pathogens in Mechanisms of Microbial Disease. Shaechter M, Medoff G, Eisenstein B I. Second Edition. Williams & Wilkins. Baltimore, Maryland. USA. 1989; 350-357.

Information

SCImago Journal & Country Rank

0.6
2020CiteScore
 
 
28th percentile
Powered by  Scopus
Redib Widget
Tutorials

Autors:

How send article?

Evaluator pair

How to evaluate an article?

Keywords

QR code

Current Issue

Perfil de Google Scholar

Most read in the last 30 days

Sistema OJS 3.4.0.3 - Metabiblioteca |